1-((2R,3R,4S,5S)-5-((S)-((2S,3R,4S,5R)-5-(aminomethyl)-3,4-dihydroxytetrahydrofuran-2-yloxy)(1-(5-(4-benzoylphenoxy)pentyl)-1H-1,2,3-triazol-4-yl)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione

ID: ALA4466347

Chembl Id: CHEMBL4466347

PubChem CID: 72701429

Max Phase: Preclinical

Molecular Formula: C34H40N6O11

Molecular Weight: 708.73

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  NC[C@H]1O[C@@H](O[C@@H](c2cn(CCCCCOc3ccc(C(=O)c4ccccc4)cc3)nn2)[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)[C@H](O)[C@@H]2O)[C@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C34H40N6O11/c35-17-23-26(43)29(46)33(49-23)51-30(31-27(44)28(45)32(50-31)40-15-13-24(41)36-34(40)47)22-18-39(38-37-22)14-5-2-6-16-48-21-11-9-20(10-12-21)25(42)19-7-3-1-4-8-19/h1,3-4,7-13,15,18,23,26-33,43-46H,2,5-6,14,16-17,35H2,(H,36,41,47)/t23-,26-,27+,28-,29-,30+,31+,32-,33+/m1/s1

Standard InChI Key:  YHDSTBXXZLKRQU-ZDJXJEJPSA-N

Alternative Forms

1. Alternative Forms:

   

   ALA4466347

   1-[(2R,3R,4S,5S)-5-[(S)-[(2S,3R,4S,5R)-5-(aminomethyl)-3,4-dihydroxyoxolan-2-yl]oxy-[1-[5-(4-benzoylphenoxy)pentyl]triazol-4-yl]methyl]-3,4-dihydroxyoxolan-2-yl]pyrimidine-2,4-dione;2,2,2-trifluoroacetic acid

2. Parent:

   

   ALA4466347

   1-[(2R,3R,4S,5S)-5-[(S)-[(2S,3R,4S,5R)-5-(aminomethyl)-3,4-dihydroxyoxolan-2-yl]oxy-[1-[5-(4-benzoylphenoxy)pentyl]triazol-4-yl]methyl]-3,4-dihydroxyoxolan-2-yl]pyrimidine-2,4-dione

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 708.73

Molecular Weight (Monoisotopic): 708.2755

AlogP: -0.61

#Rotatable Bonds: 15

Polar Surface Area: 246.50

Molecular Species: BASE

HBA: 16

HBD: 6

#RO5 Violations: 3

HBA (Lipinski): 17

HBD (Lipinski): 7

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 9.70

CX Basic pKa: 8.75

CX LogP: 0.24

CX LogD: -0.88

Aromatic Rings: 4

Heavy Atoms: 51

QED Weighted: 0.07

Np Likeness Score: 0.26

References

1. Patel B, Ryan P, Makwana V, Zunk M, Rudrawar S, Grant G..  (2019)  Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY.,  171  [PMID:30933853] [10.1016/j.ejmech.2019.01.071]

Source

Source(1):

• Scientific Literature